Individuals with the highest Atherogenic Index of Plasma had a significantly elevated risk of major adverse cardiovascular events compared to those with the lowest (HR 1.33; 95% CI 1.22-1.46).
Meta-Analysis (n=901,640)
Does the highest Atherogenic Index of Plasma (AIP) increase the risk of major adverse cardiovascular events and mortality compared to the lowest AIP in the general population?
Elevated Atherogenic Index of Plasma is an independent predictor of MACEs, coronary heart disease, and mortality in the general population.
Effect estimate: HR 1.33 (95% CI 1.22-1.46)
Introduction: The balance between plasma triglycerides and high-density lipoprotein cholesterol is evaluated using the Atherogenic Index of Plasma (AIP). We aimed to synthesize evidence from meta-analyses on the association between the AIP and major adverse cardiovascular events (MACEs) or mortality in the general population. Methods: Embase, Web of Science, and PubMed were searched for publications up to January 28, 2025. Cohort studies reporting the association between AIP and the risks of MACEs and mortality in the general population were included. Results: Fifteen studies (16 articles), encompassing a total of 901,640 individuals, met the inclusion criteria. Comparing individuals with the highest AIP to those with the lowest, the pooled adjusted HR indicated significantly elevated risks MACEs (hazard ratios HR 1.33; 95confidence intervals CI 1.22-1.46), coronary heart disease (CHD) (HR 1.72; 95% CI 1.51-1.95), stroke (HR 1.49; 95% CI 1.03-2.15), all-cause mortality (HR 1.24; 95% CI 1.10-1.39), and cardiovascular mortality (HR 1.17; 95% CI 1.05-1.31). However, the observed association between elevated AIP and stroke was not confirmed in the sensitivity analysis. Discussion: These findings suggest that measuring blood AIP level may help identify high-risk individuals for death and cardiovascular events in the general population. However, the results of subgroup analyses should be interpreted cautiously due to the limited number of studies available within each subgroup. Conclusion: Elevated AIP is an independent predictor of MACEs, CHD, cardiovascular mortality, and all-cause mortality in the general population. Further prospective studies are essential to validate these findings and to optimize the clinical application of AIP.
Cai et al. (Fri,) conducted a meta-analysis in General population (n=901,640). Highest Atherogenic Index of Plasma (AIP) vs. Lowest Atherogenic Index of Plasma (AIP) was evaluated on Major adverse cardiovascular events (MACEs) (HR 1.33, 95% CI 1.22-1.46). Individuals with the highest Atherogenic Index of Plasma had a significantly elevated risk of major adverse cardiovascular events compared to those with the lowest (HR 1.33; 95% CI 1.22-1.46).